Details for New Drug Application (NDA): 022206
✉ Email this page to a colleague
The generic ingredient in RAPAFLO is silodosin. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the silodosin profile page.
Pharmacology for NDA: 022206
Mechanism of Action | Adrenergic alpha-Antagonists |
Suppliers and Packaging for NDA: 022206
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RAPAFLO | silodosin | CAPSULE;ORAL | 022206 | NDA | Allergan, Inc. | 0023-6142 | 0023-6142-30 | 30 CAPSULE in 1 BOTTLE, UNIT-DOSE (0023-6142-30) |
RAPAFLO | silodosin | CAPSULE;ORAL | 022206 | NDA | Allergan, Inc. | 0023-6147 | 0023-6147-30 | 30 CAPSULE in 1 BOTTLE, UNIT-DOSE (0023-6147-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 4MG | ||||
Approval Date: | Oct 8, 2008 | TE: | AB | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 8MG | ||||
Approval Date: | Oct 8, 2008 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 022206
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-002 | Oct 8, 2008 | 5,403,847 | ⤷ Subscribe |
Abbvie | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-001 | Oct 8, 2008 | 5,387,603 | ⤷ Subscribe |
Abbvie | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-002 | Oct 8, 2008 | 6,015,819 | ⤷ Subscribe |
Abbvie | RAPAFLO | silodosin | CAPSULE;ORAL | 022206-002 | Oct 8, 2008 | 5,387,603 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription